newsfilter
← Latest News
Business Wire·

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

- Successfully completed enrollment of 36 participants in Phase 2 study of CYB004, the Company's deuterated dimethyltryptamine ("DMT") program for the treatment of Generalized Anxiety Disorder ("GAD"). Topline data